背景:尚未研究外周血祖细胞动员对免疫球蛋白E(IgE)反应的作用。
方法:血液淋巴细胞的分布(CD4+,CD8+,CD8+CD60+,CD19+,CD23+,CD16/56+,CD25,CD45RA+,CD45RO+,CD34+),和血清免疫球蛋白水平(IgM,IgG,IgA,IgE)在(30天)之前接受常规干细胞动员方案(美国血液学会)的过敏性哮喘血清IgE(181IU/mL)成人(m/45y/o)供体中进行了研究,在(第4天),和(最后一次剂量后1周)非格司亭(皮下,480mcg,2qd)处理(流式细胞术,比浊法,UniCAP总IgE荧光酶免疫测定)。
结果:在非格司亭治疗的第4天,与治疗前相比,CD8+CD60+T细胞和CD23+血细胞的数量显著增加(分别为98%和240%)。相反,在治疗的第4天,血清IgE水平与治疗前相比降低(>50%)。CD8+CD60+T细胞和CD23+血细胞和血清IgE水平在治疗后1周接近治疗前水平。
结论:Filgrastim治疗可短暂增加CD8+CD60+T和CD23+表达细胞的数量,已知可以调节人类IgE反应,同时也暂时抑制正在进行的IgE反应。这些结果表明非格司亭影响IgE相关反应,并可用于调节过敏反应。
BACKGROUND: The role of peripheral blood progenitor cell mobilization on Immunoglobulin E (IgE) responses has not been studied.
METHODS: Distributions of blood lymphocytes (CD4+, CD8+, CD8+CD60+, CD19+, CD23+, CD16/56+, CD25, CD45RA+, CD45RO+, CD34+), and levels of serum immunoglobulins (IgM, IgG, IgA, IgE) were studied in an allergic asthmatic serum IgE+ (181IU/mL) adult (m/45 y/o) donor undergoing routine stem cell mobilization protocol (American Society of Hematology) before (day-30), during (day 4), and after (1 wk post last dose) filgrastim (subcutaneous, 480 mcg, 2qd) treatment (flow cytometry, nephelometry, UniCAP Total IgE Fluoro enzyme immunoassay).
RESULTS: On day 4 of filgrastim treatment, numbers of CD8+CD60+T cells and CD23+ blood cells dramatically increased (98% and 240% respectively) compared with pre treatment. In contrast on day 4 of treatment, serum IgE levels decreased (>50%) compared with pre treatment. CD8+CD60+T cells and CD23+ blood cells and serum IgE levels approached pre-treatment levels at 1 week post treatment.
CONCLUSIONS: Filgrastim treatment transiently increases numbers of CD8+CD60+T and CD23+ expressing cells, which are known to regulate human IgE responses, while also transiently suppressing ongoing IgE responses. These results suggest that filgrastim affects IgE related responses, and may be useful in modulating allergic responses.